Rivastigmine Tartrate Capsule
Product Images NDC 71209-014

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 71209-014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cadila Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig1 (Rivastigmine Spl Fig1)

The text shows a graph measuring clinical improvement and decline during treatment. The horizontal axis represents the weeks during treatment, while the vertical axis represents the mean (1 SEM) change from baseline in ADAS-cog rating. The text doesn't provide further information.*

FDA Label Image

Fig2 (Rivastigmine Spl Fig2)

This appears to be a chart showing the cumulative percentage of patients who experienced a change in ADAS (Alzheimer's Disease Assessment Scale) score below 0. The chart also displays data for three treatment groups, identified as "Placebo", "t4mgdy", and "& ef2mgdy". The chart also includes a horizontal axis representing the change from baseline, with values ranging from -25 to 30.*

FDA Label Image

Fig3 (Rivastigmine Spl Fig3)

FDA Label Image

Fig4 (Rivastigmine Spl Fig4)

FDA Label Image

Fig5 (Rivastigmine Spl Fig5)

FDA Label Image

Fig6 (Rivastigmine Spl Fig6)

FDA Label Image

Fig7 (Rivastigmine Spl Fig7)

FDA Label Image

Fig8 (Rivastigmine Spl Fig8)

FDA Label Image

Rivastigmine-spl-label-60cap-1-5mg (Rivastigmine Spl Label 60cap 1 5mg)

This is a medication called Rivastigmine Tartrate in capsule form with a dosage of 1.5 mg. The medication is intended for prescription use only and should be stored at a temperature between 15°C to 30°C. The container should be tightly closed as per the USP standards. The manufacturer of this medication is Cadila Pharmaceuticals LTD in Gujarat State, India. For instructions on dosage and administration, refer to the prescribing information.*

FDA Label Image

Rivastigmine-spl-label-60cap-3mg (Rivastigmine Spl Label 60cap 3mg)

Each capsule of this medication contains 3 mg of Rivastigmine Tartrate, which is commonly used to treat patients with Alzheimer's and Parkinson's diseases. The recommended dosage can be found in the prescribing information, and the medication should be stored at room temperature in a tightly sealed container. This medication is manufactured by Cadila Pharmaceuticals LTD in India and is available only by prescription. The National Drug Code (NDC) for this product is 71209-013-03.*

FDA Label Image

Rivastigmine-spl-label-60cap-4-5mg (Rivastigmine Spl Label 60cap 4 5mg)

Each capsule contains 4.5 mg of Rivastigmine Tartrate USP. The usual dosage information is available in the prescribing information. It should be stored in a tight container at 25°C (77°F) with allowed excursions between 15 to 30°C (59 to 86°F). Manufactured by CADILA PHARMACEUTICALS LTD. in Gujarat State, INDIA. Dispensed as Rx only. NDC code is 71209-014-03.*

FDA Label Image

Rivastigmine-spl-label-60cap-6mg (Rivastigmine Spl Label 60cap 6mg)

These are Rivastigmine Tartrate Capsules USP, corresponding to 6mg of Rivastigmine per capsule. They should be stored between 15-30°C (59-86°F). The usual dosage should be determined by the prescribing physician. They come in a bottle of 60 capsules and were manufactured by Cadila Pharmaceuticals LTD in India.*

FDA Label Image

Str (Rivastigmine Spl Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.